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Abstract
Background: Prognostic nutritional index has been shown to be a prognostic marker for various solid tumors.
However, few studies have investigated the impact of the prognostic nutritional index on survival of patients with
breast cancer. The aim of this study was to investigate the impact of the prognostic nutritional index on the
long-term outcomes in patients with breast cancer.
Methods: This study reviewed the medical records of 212 patients with breast cancer who underwent mastectomy.
The prognostic nutritional index was calculated as 10 × serum albumin (g/dl) + 0.005 × total lymphocyte count
(per mm3). Receiver operating characteristic curve analysis was performed to determine the cutoff value of the
prognostic nutritional index. The survival curves were calculated by the Kaplan–Meier method. Differences between
the curves were analyzed by the log-rank test. Multivariate Cox proportional hazard model was used to evaluate the
prognostic significance of prognostic nutritional index in patients with breast cancer.
Results: The mean prognostic nutritional index just before the operation was 51.9, and the median follow-up after
surgery was 47.7 months. The optimal cutoff value of the prognostic nutritional index for predicting the overall
survival was 52.8 from the receiver operating characteristic curve analysis. The 5-year overall survival rate was 98.
3 % in the prognostic nutritional index >52.8 and 92.0 % in the prognostic nutritional index <52.8 (P = 0.013). In
the multivariate analysis, a low prognostic nutritional index was an independent predictor for poor overall
survival (HR, 5.88; 95 % CI, 1.13–108.01; P = 0.033).
Conclusions: The prognostic nutritional index is a simple and useful marker for predicting the long-term
outcomes of breast cancer patients, independent of the tumor stage.
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Background
Breast cancer is the most frequently diagnosed malignancy
and is the leading cause of cancer death among women
[1]. The prognosis of breast cancer is influenced by well-
recognized host- and tumor-related factors, including
patient age, histological type and grade, tumor size, lymph
node status, estrogen receptor (ER) and progesterone
receptor (PR) status, and human epidermal growth factor
receptor 2 (HER2) status [2]. Despite recent improve-
ments in early detection, progress in surgical techniques,
chemotherapy, and endocrine therapy, some patients
with breast cancer develop recurrence, even after cura-
tive resection. Therefore, accurate prediction of prog-
nosis is needed to improve patient survival and to
provide important information to the patients.
Serum albumin is one of the most commonly used
markers for assessing nutritional status. Albumin is
produced by the liver and is the major protein in blood,
acting as a key antioxidant, detoxifier, and transporter
of important nutrients. In advanced cancer patients, the
levels of serum albumin fall sharply because malnutri-
tion and systematic inflammatory response to tumors
both suppress albumin synthesis [3]. The prevalence of
malnutrition among breast cancer patients reported by
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two studies was 20.5 % [4] and 18.3 % [5], respectively.
A Korean study also showed that >51 % of female
breast cancer patients had moderate to high risk of
malnutrition [6]. Malnutrition can cause many clinical
consequences, including decreased quality of life, re-
duced treatment response, and increased treatment-
related toxicity. The prognostic nutritional index (PNI),
which is based on serum albumin concentration and
total peripheral lymphocyte count, was originally pro-
posed to assess the perioperative immunological status
and surgical risk in patients undergoing gastrointestinal
surgery [7]. Recently, the PNI has been shown to be a
prognostic marker for various solid tumors [8–10].
However, few studies have investigated the impact of
the PNI on survival of patients with breast cancer.
Therefore, we retrospectively investigated the correl-
ation between the PNI and clinicopathological factors




A total of 219 patients with histologically confirmed breast
cancer underwent surgery between January 2006 and
October 2015 at the Department of Surgery, Toyama
Hospital, Japan. We excluded seven patients with distant
metastasis. Therefore, 212 patients were analyzed in this
study. The median age was 66 (range 27–96) years. Most
patients received adjuvant chemotherapy and/or endo-
crine therapy according to the clinical practice guidelines
for breast cancer from the Japanese Breast Cancer Society
[11], if necessary.
Data collection
Clinicopathological characteristics were obtained retro-
spectively from the medical records and evaluated as
prognostic factors; these included patient age, tumor
size, lymph node metastasis, pathological stage, hormo-
nal receptor status (ER and PR), and HER2 status. The
stage of breast cancer was classified according to the 7th
edition of American Joint Committee on Cancer TNM
Classification System [12].
We also collected data from blood tests just before the
operation, including the level of serum albumin, total
peripheral lymphocyte count, and carcinoembryonic
antigen (CEA) and carbohydrate antigen (CA) 15-3
levels. PNI was calculated using the following formula:
10 × serum albumin value (g/dl) + 0.005 × total lympho-
cyte count in the peripheral blood (per mm3).
Statistical analysis
The categorical variables were presented as numbers and
percentages, and the groups were compared using the χ2
test. Continuous variables with normal distribution were
expressed as the mean and standard deviation (SD) and
were compared using the Mann–Whitney U test or
Kruskal–Wallis test.
At the time of the final follow-up (February 2016), the
median follow-up was 47.7 months. Overall survival
(OS) was defined as the time from the operation until
death. Disease-free survival (DFS) was defined as the
time from the operation to disease recurrence. In DFS
analysis, the patients who died of any other cause rather
than breast cancer were excluded. The survival curves
were calculated by the Kaplan–Meier method. Differ-
ences between the curves were analyzed by the log-rank
test. To evaluate the sensitivity and specificity for OS
and DFS, the receiver operating characteristic (ROC)
curve was calculated, and the Youden index was esti-
mated to determine the optimal cutoff value for the PNI.
Univariate associations with long-term survival were
determined using Kaplan–Meier analysis and the log-
rank test. Multivariable analyses were performed by Cox
proportional hazards regression analysis, incorporating
Table 1 Relationship between clinicopathological factors and PNI
Variables n (%) PNI, mean ± SD P value
Age (year) ≦65 102 (48) 53.1 ± 4.1 <0.001
>65 110 (52) 50.8 ± 5.2
Histology Ductal 191 (90) 51.9 ± 4.7 0.291
Lobular 9 (4) 49.2 ± 5.0
Special 12 (6) 53.4 ± 6.2
Tumor size (cm) ≦2 145 (68) 52.3 ± 4.8 0.166
>2, ≦5 61 (29) 50.9 ± 5.0
>5 6 (3) 51.7 ± 4.0
Nodal metastasis 0 168 (79) 52.0 ± 5.0 0.240
1–3 28 (13) 52.0 ± 4.4
>3 16 (8) 50.1 ± 3.7
Stage 0/I 135 (64) 52.3 ± 4.8 0.124
II 58 (27) 51.5 ± 4.9
III 19 (9) 50.5 ± 4.5
Estrogen receptor
status
Positive 168 (79) 51.8 ± 5.0 0.682
Negative 44 (21) 52.3 ± 4.4
Progesterone receptor
status
Positive 145 (68) 51.8 ± 5.0 0.879
Negative 67 (32) 52.1 ± 4.6
HER2 status Positive 39 (18) 51.0 ± 4.8 0.152
Negative 173 (82) 52.1 ± 4.8
CEA (ng/ml) <5 164 (77) 51.9 ± 4.6 0.953
≥5 48 (23) 51.9 ± 5.5
CA 15-3 (U/ml) <23 199 (94) 52.0 ± 4.8 0.327
≥23 13 (6) 50.4 ± 5.1
PNI prognostic nutritional index, ER estrogen receptor, PR progesterone
receptor, HER-2 human epidermal growth factor receptor 2
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all variables with P < 0.10 on univariate analysis. Statis-
tical significance was defined as P < 0.05. These analyses
were conducted using JMP version 11.0.0 (SAS Institute,
Cary, NC, USA).
Results
PNI and clinicopathological characteristics of patients
The mean PNI just before the operation was 51.9 (SD
4.9). Most of the 212 patients had ductal carcinoma, 67
(32 %) had a tumor >2 cm, and 44 (21 %) had axillary
lymph node metastasis. The mean PNI in patients aged
>65 years was significantly lower than that in patients
aged ≦65 years (P < 0.001; Table 1). The PNI value grad-
ually decreased with the advancing disease stage, but sig-
nificant difference was not observed (P = 0.124; Table 1).
ROC analysis
Using OS as an endpoint, the area under the ROC
curve for the PNI was 0.676. When the PNI was 52.8,
the Youden index was maximal, with a sensitivity of
91.7 % and specificity of 41.5 %. Therefore, the cutoff
value of the PNI was set at 52.8. Then, 85 patients
(40.0 %) with a PNI >52.8 and 127 patients (60.0 %)
with a PNI ≤52.8 were classified into PNI-high and PNI-
low groups, respectively. During the studied period, four
patients died of any other cause rather than breast cancer.
Those patients were excluded from DFS analysis. Using
DFS as an endpoint, the area under the ROC curve for
the PNI was 0.657. The cutoff value of the PNI on
DFS was set at 52.4. There were 90 patients with a
PNI >52.4 (a PNI-high group) and 118 patients with a
PNI ≤52.4 (a PNI-low group).
OS and DFS
The 5-year OS rate was 98.3 % in the PNI-high group
and 92.0 % in the PNI-low group (P = 0.019; Fig. 1a).
One patient (1.2 %) died in the PNI-high group, and
seven (5.5 %) died in the PNI-low group. The cause of
death in the PNI-low group was tumor relapse in four
patients, other cancer in two patients, and a cause other
than cancer in one patient. One patient in PNI-high
group died of a cause other than cancer. The 5-year DFS
rate was 97.1 % in the PNI-high group and 92.0 % in the
PNI-low group (P = 0.035; Fig. 1b).
Predictive factors for OS
In the univariate analysis, tumor size, lymph node me-
tastasis, and PNI were significantly associated with OS
(Table 2). The multivariate analysis demonstrated that
PNI and lymph node metastasis were independent
prognostic factors for the OS (Table 3).
Discussion
Our present study demonstrated that the PNI can predict
the long-term outcomes of breast cancer patients, inde-
pendent of the conventional TNM classification. The OS
and DFS rates of the PNI-low group were significantly
lower than those of the PNI-high group. The multivariate
analysis performed in the present study demonstrated that
the PNI was an independent predictor for the OS.
There are several known predictors of breast cancer
prognosis, such as tumor size, histological type, lymph
node involvement, hormonal receptor status, and HER2
status. However, it is of interest that there are other
host-related factors, such as the PNI. Previous studies
have reported an impact of the PNI on the long-term
outcomes in several solid tumors, and various cutoff
values for the PNI were used in those studies [8–10].
The cutoff value was usually set at 45, because PNI <45
is defined as moderate to severe malnutrition. However,
the optimal cutoff value of the PNI to predict the long-
term outcomes remains unclear. In the present study,
we performed a ROC curve analysis, and the optimal
cutoff value for the PNI was determined to be 52.8.
When the PNI was 52.8, the sensitivity and specificity
Fig. 1 Kaplan–Meier estimates of OS and DFS according to the PNI. a OS rate of the PNI-low group was significantly lower than that of the PNI-
high group (P = 0.019). b DFS rate of the PNI-low group was significantly lower than that of the PNI-high group (P = 0.035). Solid line indicates the
PNI-low group, and dotted line indicates the PNI-high group
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for the 5-year OS were 91.7 and 41.5 %, respectively.
Few studies have determined the prognostic impact of
the PNI in breast cancer patients. Only one study has
shown that the preoperative PNI can be used as a simple
and useful marker for predicting the long-term out-
comes of triple-negative breast cancer [13]. The present
study showed that a low preoperative PNI was associated
with a higher risk of postoperative recurrence of breast
cancer independent of hormonal receptor status and
TNM stage.
The association between decreased PNI and poor sur-
vival of breast cancer is probably complex and largely un-
clear; however, possible explanations do exist. PNI is
derived from the absolute albumin and absolute lympho-
cyte counts and is a routinely available laboratory test.
One potential mechanism underlying the prognostic
impact of PNI is that low PNI reflects hypoalbumin-
emia. Serum albumin has been used to assess disease
severity, progression, and prognosis. Another factor is
that lymphocytes play an important role in the host
immune response to eradicate the formation and pro-
gression of tumors [14]. High lymphocytic infiltration is
associated with improved survival, independent of clinico-
pathological characteristics, in primary operable ductal in-
vasive breast cancer [15]. The importance of lymphocytes
has been highlighted in several studies in which increasing
infiltration of tumors with lymphocytes was associated
with better response to cytotoxic treatment and prognosis
in breast cancer patients [16–18]. Thus, low PNI may con-
fer a survival advantage by tumor cells and lead to poorer
outcome and increased recurrence.
The major limitations of the present study were the
retrospective nature of the study and the single-center
design. We were unable to exclude the possibility that
unequal distribution of unidentified clinicopathological
parameters in our patient cohort may have biased the
results. Therefore, a large, prospective study should
therefore be performed to confirm our findings.
Conclusions
Our clinical observation shows that the PNI is associated
with OS and DFS in patients with breast cancer. The
PNI is an easy-to-determine, reproducible, and inexpen-
sive test. It can be easily incorporated into routine use as
a prognostic factor. Despite all these results, prospective
studies evaluating PNI in a large series are required in
this field.
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Table 2 Univariate analysis of prognostic factors for OS




















































OS overall survival, ER estrogen receptor, PR progesterone receptor, HER-2
human epidermal growth factor receptor 2, CEA carcinoembryonic antigen, CA
15-3 carbohydrate antigen 15-3, PNI prognostic nutritional index
Table 3 Cox proportional multivariate hazard models for OS
Variables Hazard ratio 95 % CI P value
Age >65 11.9 2.23–220.81 0.002
Tumor size >2 cm 1.94 0.45–8.91 0.377
Lymph node metastasis Positive 4.06 1.05–17.86 0.042
PNI ≦52.8 5.88 1.13–108.01 0.033
CI confidence interval, PNI prognostic nutritional index
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